Üre Döngüsü Bozuklukları
Özet
Üre döngüsü bozuklukları, atık nitrojenin vücuttan atılmasını sağlayan mekanizmadaki enzim veya taşıyıcı protein eksikliklerinden kaynaklanan ciddi metabolik hastalıklardır. Toksik amonyak birikimi (hiperamonyemi) ile karakterize olan bu durum, yenidoğanlarda ağır klinik tablolara veya geç başlangıçlı nörolojik sorunlara yol açabilir. Tanı genellikle klinik şüphe ve metabolik analizlerle konulurken, tedavi protein kısıtlaması, ilaç desteği, diyaliz ve ciddi vakalarda karaciğer naklini içermektedir. Erken teşhis ve yönetim, yüksek mortalite ve morbidite oranlarına sahip bu hastalıkların prognozu için kritik öneme sahiptir.
Urea cycle disorders are serious metabolic conditions resulting from enzyme or transporter protein deficiencies in the nitrogen detoxification mechanism, leading to toxic ammonia accumulation. Characterized by hyperammonemia, these disorders can manifest as severe neonatal emergencies or late-onset neuropsychiatric symptoms. Diagnosis relies on clinical suspicion and metabolic analysis, while treatment involves protein restriction, pharmacological support, dialysis, and potentially liver transplantation in severe cases. Early detection and management are critical for improving the prognosis of these conditions, which carry high risks of morbidity and mortality.
Referanslar
Krebs HA, Henseleit K. Untersuchungen über die Harnstoffbildung im Tierkörper. Klin Woche. 1932;ume 11(Issue 18):757–759.
Matsumoto S, Häberle J, Kido J, Mitsubuchi H, Endo F, Nakamura K. Urea cycle disorders-update. J Hum Genet. 2019 Sep;64(9):833-847.
Haberle J, Rubio V. Disorders of the Urea Cycle and Related Enzymes. In: Saudubray JM., Baumgartner MR., Walter J. (eds) Inborn Metabolic Diseases. Springer, Berlin, Heidelberg, 2016. p. 295-308.
Braissant O. Current concepts in the pathogenesis of urea cycle disorders. Mol Genet Metab. 2010;100 Suppl 1:3-12.
Stone WL, Basit H, Jaishankar GB. Urea Cycle Disorders. 2021 Jan 24. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan–.
Summar ML, Koelker S, Freedenberg D, et al. Network for Intoxication Type Metabolic Diseases. Electronic address hwe-ioeip, Members of the Urea Cycle Disorders Consortium. Electronic address hreueu: The incidence of urea cycle disorders. Mol Genet Metab. 2013, 110:179-180.
Brusilow SW, Maestri NE. Urea cycle disorders: diagnosis, pathophysiology, and therapy. Adv Pediatr. 1996; 43:127-170.
Nettesheim S, Kölker S, Karall D, et al. Arbeitsgemeinschaft für Pädiatrische Stoffwechselstörungen (APS); European registry and network for Intoxication type Metabolic Diseases (E-IMD); Erhebungseinheit für Seltene Pädiatrische Erkrankungen in Deutschland (ESPED); Austrian Metabolic Group; Swiss Paediatric Surveillance Unit (SPSU). Incidence, disease onset and short-term outcome in urea cycle disorders -cross-border surveillance in Germany, Austria and Switzerland. Orphanet J Rare Dis. 2017 Jun 15;12(1):111.
Nagata N, Matsuda I, Oyanagi K. Estimated frequency of urea cycle enzymopathies in Japan. Am J Med Genet. 1991;39:228–9.
Keskinen P, Siitonen A, Salo M. Hereditary urea cycle diseases in Finland. Acta Paediatr. 2008;97:1412–9.
Ah Mew N, Simpson KL, Gropman AL, Lanpher BC, Chapman KA, Summar ML. Urea Cycle Disorders Overview. 2003 Apr 29 [updated 2017 Jun 22]. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Mirzaa G, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2021.
Burton BK. Inborn errors of metabolism in infancy: a guide to diagnosis. Pediatrics. 1998; 102:E69.
Summar M. Current strategies for the management of neonatal urea cycle disorders. J Pediatr. 2001; 138:30-39.
Maestri NE, Lord C, Glynn M, Bale A, Brusilow SW. The phenotype of ostensibly healthy women who are carriers for ornithine transcarbamylase deficiency. Medicine (Baltimore). 1998; 77:389-97.
Serrano M, Martins C, Pérez-Dueñas B, et al. Neuropsychiatric manifestations in late-onset urea cycle disorder patients. J Child Neurol. 2010; 25:352-358.
Arn PH, Hauser ER, Thomas GH, Herman G, Hess D, Brusilow SW. Hyperammonemia in women with a mutation at the ornithine carbamoyltransferase locus. A cause of postpartum coma. N Engl J Med. 1990; 322:1652-5.
Häberle J, Burlina A, Chakrapani A, et al. Suggested guidelines for the diagnosis and management of urea cycle disorders: First revision. J Inherit Metab Dis. 2019 Nov;42(6):1192-1230.
Loeber JG, Burgard P, Cornel MC, et al. Newborn screening programmes in Europe; arguments and efforts regarding harmonization. Part 1. From blood spot to screening result. J Inherit Metab Dis. 2012;35:603–11.
Scaglia F, Brunetti-Pierri N, Kleppe S, et al. Clinical consequences of urea cycle enzyme deficiencies and potential links to arginine and nitric oxide metabolism. J Nutr. 2004; 134:2775-2782.
Hudak ML, Jones MD Jr, Brusilow SW. Differentiation of transient hyperammonemia of the newborn and urea cycle enzyme defects by clinical presentation. J Pediatr. 1985, 107: 712-719.
Summar ML, Barr F, Dawling S, et al. Unmasked adult-onset urea cycle disorders in the critical care setting. Crit Care Clin. 2005; 21:1-8.
Summar ML, Dobbelaere D, Brusilow S, Lee B. Diagnosis, symptoms, frequency and mortality of 260 patients with urea cycle disorders from a 21-year, multicentre study of acute hyperammonaemic episodes. Acta Paediatr. 2008;97: 1420-1425
Tuchman M, Georgieff MK. Transient hyperammonemia of the newborn: a vascular complication of prematurity?. J Perinatol. 1992;12: 234-236.
Lee B, Diaz GA, Rhead W, et al. Glutamine and hyperammonemic crises in patients with urea cycle disorders. Mol Genet Metab. 2016; 117:27-32.
Kline JJ, Hug G, Schubert WK, Berry H. Arginine deficiency syndrome. Its occurrence in carbamyl phosphate synthetase deficiency. Am J Dis Child. 1981; 135:437-442.
Nassogne MC, Héron B, Touati G, Rabier D, Saudubray JM. Urea cycle defects: management and outcome. J Inherit Metab Dis. 2005; 28:407-414.
Singh RH. Nutritional management of patients with urea cycle disorders. J Inherit Metab Dis. 2007; 30:880-887.
Berry GT, Steiner RD. Long-term management of patients with urea cycle disorders. J Pediatr. 2001; 138:56-60.
Kido J, Nakamura K, Mitsubuchi H, et al. Long-term outcome and intervention of urea cycle disorders in Japan. J Inherit Metab Dis. 2012; 35:777-785.
Whitington PF, Alonso EM, Boyle JT, et al. Liver transplantation for the treatment of urea cycle disorders. J Inherit Metab Dis. 1998;21(Suppl 1):112–118.
Noujaim HM, Mayer DA, Buckles JA, et al. Techniques for and outcome of liver transplantation in neonates and infants weighing up to 5 kilograms. J Pediatr Surg. 2002;37:159–164.
Lee B, Dennis JA, Healy PJ, et al. Hepatocyte gene therapy in a large animal: a neonatal bovine model of citrullinemia. Proc Natl Acad Sci. 1999;96:3981–3986.
Cunningham SC, Kok CY, Dane AP, et al. Induction and prevention of severe hyperammonemia in the spfash mouse model of ornithine transcarbamylase deficiency using shRNA and rAAV-mediated gene delivery. Mol Ther. 2011;19:854–859.
Raper SE, Yudkoff M, Chirmule N, et al. A pilot study of in vivo liverdirected gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency. Hum Gene Ther. 2002;13:163–175.
Uchino T, Endo F, Matsuda I. Neurodevelopmental outcome of long-term therapy of urea cycle disorders in Japan. J Inherit Metab Dis. 1998; 21 Suppl 1:151-159.
